Sustained virologic response ( SVR ) @ weeks after end of treatment ( SVR@ ) , including patients treated with @ or @ additional weeks of peginterferon + ribavirin , was @ % for TRIPLE ( VX-@ @ mg twice daily ) and @ and @ % for QUAD ( VX-@ @ and @ mg twice daily , respectively ) .